Skip to main content
SpringerLink
Log in

Deferasirox: a guide to its use in transfusional chronic iron overload

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Yang LPH, Keam SJ, Keating GM. Deferasirox: a review of its use in the management of transfusional chronic iron overload [published erratum appears in Drugs 2007; 67 (16): 2333]. Drugs 2007; 67(15): 2211–30

    Article  PubMed  CAS  Google Scholar 

  2. Roberts DJ, Rees D, Howard J, et al. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusiondependent thalassaemia. Cochrane Database System Rev 2005; (4): CD004450

  3. Roberts DJ, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database System Rev 2007 Jul 18; (3): CD004839

  4. European Medicines Agency. Exjade: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Dec 17]

  5. Exjades R (deferasirox tablets for oral suspension): US prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, 2007 Apr

  6. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006 May 1; 107(9): 3455–62

    Article  PubMed  CAS  Google Scholar 

  7. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006 Jul; 91(7): 873–80

    PubMed  CAS  Google Scholar 

  8. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003 Jun; 43(6): 565–72

    PubMed  CAS  Google Scholar 

  9. Important information about Exjade (deferasirox) tablets for oral suspension [online]. Available from URL: http://www.fda.gov [Accessed 2007 Dec 17]

  10. Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade®), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload [abstract no. 3193]. Blood 2004 Nov 16; 104 (11 Pt 1): 872a. Plus poster presented at the 46th Annual Meeting and Exposition of the American Society of Hematology; 2004 Dec 4–7; San Diego (CA)

    Google Scholar 

  11. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007 Feb; 136(3): 501–8

    Article  PubMed  CAS  Google Scholar 

  12. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica 2006 Oct; 91(10): 1343–51

    PubMed  CAS  Google Scholar 

  13. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001: 47-61

  14. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006 May 1; 107(9): 3436–41

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deferasirox: a guide to its use in transfusional chronic iron overload. Drugs Ther. Perspect 24, 1–4 (2008). https://doi.org/10.2165/00042310-200824020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824020-00001

Keywords

Search

Navigation